Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669238 | 1.00 | ADORA2A (0.43) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4944986 | 0.92 | ADORA2A (0.43) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4947770 | 0.92 | ADORA2A (0.43) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4944980 | 0.92 | ADORA2A (0.43) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL16192629 | 0.91 | ADORA2A (0.42) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4950553 | 0.91 | ADORA2A (0.42) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4949356 | 0.90 | PDE5A (0.43) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4944961 | 0.89 | ADORA2A (0.48) | ADORA2AADORA2BADORA1ADORA3HTR1A | |
| SCHEMBL4636327 | 0.88 | ADORA1 (0.53) | ADORA2AADORA2BADORA1ADORA3MAOB | |
| SCHEMBL4636332 | 0.88 | ADORA1 (0.53) | ADORA2AADORA2BADORA1ADORA3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1939197-A1 | 8-ethinylxanthine derivatives as selective A2A receptor antagonists | SCHWARZ PHARMA AG (DE) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | ADORA2A 115/4885ADORA2B 279/4885ADORA1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.